NSAIDs in cardiovascular diseases
NSAIDs in cardiovascular diseases
Sa pangunahing (esensyal) na altapresyon, ito ay dahil sa impluwensya ng namamana, hilig sa mataas na presyon ng dugo sa konteksto ng hindi malusog na pamumuhay, masamang gawi, hindi malusog na pagkain, na nagdudulot ng labis na timbang. Dagdag pa ang stress, kalikasan, kakulangan sa tulog at aktibidad. Lahat ito ay negatibong nakakaapekto sa trabaho ng puso at sa tono ng mga daluyan ng dugo. Ang presyon ay unang tumataas nang hindi napapansin at pagkatapos ay mas nagiging malinaw.
>>> ПЕРЕЙТИ НА ОФИЦИАЛЬНЫЙ САЙТ <<<
NSAIDs in cardiovascular disease: risks and clinical implications Non-steroidal anti-inflammatory Drugs (NSAIDs) are among the most commonly used drugs worldwide and are mainly used for the treatment of pain, inflammation and fever. Despite their wide distribution and OTC availability (over‑the‑counter) you are associated with a number of side effects, particularly in patients with existing cardiovascular disease (CVD). Pharmacological mechanisms of action and cardiovascular effects The effect of the NSAIDs is based on the inhibition of the Cyclooxygenase enzymes (COX‑1 and COX‑2), for the synthesis of prostaglandins responsible. Prostaglandins play an important role in the Regulation of vascular tone, platelet aggregation and Renal blood flow. The selective or non-selective inhibition of these enzymes can trigger the following cardiovascular effects: Increase in blood pressure through a reduction in vasodilator of prostaglandins and decreased renal function. Fluid retention: due to changes in renal perfusion and increased sodium retention. Thromboembolic events: in particular, in the case of selective COX‑2 inhibitors, which affect platelet function less, but the production of prostacyclin (PGI₂) in the vessel to inhibit walls. Epidemiological Evidence Several large observational studies and meta-analyses have shown that the intake is associated with the NSAIDs with an increased risk for cardiovascular events. In particular: an increased risk for myocardial infarction (MI), a higher incidence of stroke, an increase of congestive heart failure exacerbations, a possible risk for arrhythmic events. The risk seems to be dose and duration of intake and the specific NSAIDs to hang out. For example, it was described for Diclofenac significantly higher cardiovascular risk than for Naproxen. Risk groups Particularly patients with risk: of existing coronary heart disease (CHD), arterial hypertension, Diabetes mellitus, chronic renal failure Congestive heart failure. Also, elderly patients are exposed to due to Comorbidities and altered pharmacokinetics with an increased risk. Clinical Recommendations Before the regulation of NSAIDs, a careful Benefit-risk assessment should be performed, especially in patients with CVD or elevated cardiovascular risk profile. Recommendations include: The lowest effective dose for the shortest possible duration. Waiver of COX‑2‑selective inhibitors in patients with hollow cardiovascular risk. Preference for Naproxen in some cases, because it has a more favourable cardiovascular profile (but with an increased gastrointestinal risk). Regular monitoring of blood pressure, of renal function, and of Edema during therapy. Educating the patients about the symptoms of cardiovascular complications (e.g., chest pain, shortness of breath, sudden swelling). Conclusion NSAIDs can cause in patients with cardiovascular disease to significant cardiovascular side effects. An individual risk assessment in a differentiated Medicines selection and close Monitoring are crucial to ensure the safety of these drugs in clinical practice. Further research is needed to understand the long-term effects of various NSAIDs on the cardiovascular System.
If you have disturbed sleep, fatigue, disorientation, confusion, or nervousness, it's time to monitor your blood pressure. Either lack of sleep or too much sleeping might mean your blood pressure is high or low. If it’s left untreated, you will soon face an onslaught of multiple illnesses. NSAIDs in cardiovascular diseases. Nililinis ang mga ugat na kailangang alagaan mula sa deposito at pinananatili ang kinakailangang lakas ng tibok ng puso!
Hypertension high blood pressure
Cardiovascular diseases, first aid, briefly
Нпвпн and cardiovascular disease questions from patients
What are the medications for high blood pressure can cause cough
http://silvernz.beget.tech/articles/45228-in-the-case-of-high-blood-pressure-dizziness.html
https://dem0s.ru/posts/6400-medications-for-cardiovascular-disease.html
Minsan, dinadagdagan ng doktor ang base na therapy (mga gamot na kailangang inumin araw-araw) ng mga gamot na iniinom kapag may krisis, kapag ang presyon ay sobrang taas at biglang tumaas. At ang dosis ay pinipili rin nang napaka-indibidwal. Kaya imposible na sabihin kung alin ang pinakamahusay na gamot sa presyon, sa bawat kaso ay magkakaroon ng sariling kombinasyon na bagay sa iyo. Una sa lahat, ang mga Beta-blocker ay karaniwang ibinibigay sa mga pasyente na may heart failure, aortic aneurysm, pagkatapos ng myocardial infarction, at sa mga kababaihan na nasa edad ng pagbubuntis, lalo na sa mga kababaihang nagpaplano ng pagbubuntis. Madalas matanggap ng katawan ang Beta-blocker, pero maaari rin itong magdulot ng pantal sa balat at bradycardia – sobrang bagal ng tibok ng puso.
Literature review: Cardiovascular Disorders: A Review Of The Literature Cardiovascular diseases (CVD) are one of the leading causes of death worldwide and represent a major challenge for the health system. This Literature review deals with the current scientific knowledge to disease risk factors, diagnostic methods and treatment strategies for cardiovascular disease. Risk factors and epidemiology According to the results of several epidemiological studies of modifiable and non-modifiable risk factors play a crucial role in the pathogenesis of CVD. Among the most important modifiable factors: Hypertension (blood pressure≥140/90 mmHg), Hyperlipidemia (elevated concentration of LDL‑cholesterol), Diabetes mellitus type 2, Smoking Overweight and obesity (BMI ≥30 kg/m 2 ), physical inactivity, unhealthy diet. Non-modifiable factors include age, gender (men are at the age of 65. Age at greater risk), and family history of early cardiovascular events. A study by the World Health Organization (WHO, 2023) estimates that more than 17 million deaths each year are due to cardiovascular disease, which accounts for about 30% of all Global deaths. Diagnostic Procedures The modern diagnosis of CVD is based on a combination of different methods: History and physical examination: evaluation of risk factors, symptoms, and cardiovascular signs. Laboratory analyses: measurement of lipid profiles, blood sugar, kidney values and specific biomarkers such as Troponin and NT‑proBNP. Electrocardiogram (ECG): for the detection of arrhythmias, signs of ischemia or infarction follow. Echocardiography: imaging method for the assessment of cardiac structure and function. Load tests (e.g., treadmill test): for the functional assessment under load. Coronary angiography: invasive method for direct visualization of narrowings in the coronary arteries. Therapeutic Approaches The treatment of CVD includes pharmacological and interventional measures: Drugs: Antihypertensive (ACE inhibitors, beta-blockers), Lipid-Lowering Drugs (Statins), Antidiabetic agents Platelet aggregation inhibitors (e.g., acetylsalicylic acid). Interventional Procedures: Percutaneous coronary Intervention (PCI) with stent implantation, Coronary bypass surgery (CABG). Life style modifications: Smoking abstinence a healthy diet (e.g., DASH diet), regular physical activity (at least 150 minutes of moderate load per week), Weight control. Current Research Trends Recent studies focus on the development of more precise risk stratification methods, the use of Artificial intelligence for the analysis of ECG data, as well as the study of genetic and epigenetic factors in CVD. In addition, new drugs, such as PCSK9 inhibitors for aggressive LDL reduction are investigated intensively. Conclusion Scientific progress has led to significant improvements in the prevention, diagnosis and therapy of cardiovascular diseases. Nevertheless, the reduction of risk factors and the promotion of a healthy life style the most important measure to reduce the morbidity and mortality due to CVD. Further research is necessary to optimize individual treatment approaches and to improve the quality of life in a sustainable way. Sources (Examples) WHO (2023): Global Health Estimates. German heart Foundation (2022): guidelines for the prevention of cardiovascular diseases. European Society of Cardiology (2021): Guidelines on cardiovascular disease prevention.